Dexcom vs Medline (DXCM vs MDLN)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Medline is the larger company by revenue ($28.4B vs $4.7B) and market value ($72.3B vs $28.9B). Dexcom runs the higher operating margin (19.6% vs 7.8%). Dexcom trades at the lower trailing P/E (32.2x vs 35.3x).
About Dexcom
Dexcom Inc is a medical device company that designs, develops, and sells continuous glucose monitoring systems for diabetes and metabolic health management. Its main products include the Dexcom G7 and G7 15 Day systems, which provide real-time glucose readings and alerts to patients, caregivers, and clinicians. The company serves people with diabetes, including those using insulin, as well as adults with prediabetes and Type 2 diabetes who do not use insulin.
About Medline
Medline Inc. is a provider of medical-surgical products and supply chain solutions serving various healthcare settings such as hospitals, surgery centers, and physician offices. The company offers approximately 335,000 products, including surgical kits, gloves, wound care items, and diagnostic equipment, through its Medline Brand and Supply Chain Solutions segments. Medline operates a network of global distribution centers and its own fleet of trucks to deliver products and supply chain services to healthcare providers.
Head to head (DXCM FY2025 vs MDLN FY2025)
| Metric | DXCMFY2025 | MDLNFY2025 |
|---|---|---|
| Revenue | $4.66B | $28.43B |
| Revenue growth (YoY) | 15.6% | — |
| Gross margin | 60.1% | 26.4% |
| Operating margin | 19.6% | 7.8% |
| Net margin | 17.9% | 4.1% |
| Net income | $836.3M | $1.16B |
| Diluted EPS | $2.09 | $-0.01 |
| FCF margin | 23.1% | 4.6% |
| ROE | 30.5% | 6.0% |
| Debt / equity | — | 0.6× |
| Market cap | $28.93B | $72.30B |
| P/E (TTM) | 32.2× | 35.3× |
Fundamentals are from each company’s SEC filings (DXCM FY2025, MDLN FY2025). P/E and market cap are derived from recent market prices and update daily.
Five-year trend (as reported)
| DXCM by fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.45B | $2.91B | $3.62B | $4.03B | $4.66B |
| Net income | $216.9M | $341.2M | $541.5M | $576.2M | $836.3M |
| Operating margin | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% |
| MDLN by fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $23.23B | $25.51B | — | $28.43B |
| Net income | $234.0M | $1.16B | $1.15B | $1.16B |
| Operating margin | 5.4% | 8.4% | — | 7.8% |
Dexcom and Medline use different fiscal calendars (DXCM's FY2025 ended 2025-12-31, MDLN's FY2025 ended 2025-12-31), so their fiscal years are shown separately rather than forced into one timeline.
Peer standing
Where each company ranks among the 88 medical device companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | DXCM | MDLN |
|---|---|---|
| Gross margin | 60.1%43rd percentile of 77 | 26.4%3rd percentile of 77 |
| Operating margin | 19.6%92nd percentile of 80 | 7.8%66th percentile of 80 |
| Net margin | 17.9%90th percentile of 81 | 4.1%66th percentile of 81 |
| FCF margin | 23.1%93rd percentile of 74 | 4.6%63rd percentile of 74 |
| ROE | 30.5%95th percentile of 79 | 6.0%65th percentile of 79 |
| P/E (TTM) | 32.2×52nd percentile of 32 | 35.3×61st percentile of 32 |
| Short interest (days to cover) | 3.60d51st percentile of 88 | 3.73d53rd percentile of 88 |
Short interest
| FINRA settlement data | DXCM | MDLN |
|---|---|---|
| Shares sold short | 18.1M | 36.3M |
| Change vs prior settlement | +6.4% | +31.3% |
| Days to cover | 3.60 | 3.73 |
| As of settlement | 2026-06-30 | 2026-06-30 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 open-market activity | DXCM | MDLN |
|---|---|---|
| Buys | 0 | 1 ($170,750) |
| Sells | 10 ($5.3M) | 14 ($3.60B) |
Open-market purchases and sales reported on SEC Form 4 (grants, exercises and tax withholding excluded). For context, about 16% of covered companies saw any open-market insider buy in a 90-day window.
Held by the same investors
6 tracked 13F managers hold both Dexcom and Medline as of their latest quarterly filings: Citadel Advisors, Gotham Asset Management, Millennium Management, Point72 Asset Management, Renaissance Technologies, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
BDX vs DXCMBSX vs DXCMDXCM vs MMMDXCM vs RMDDXCM vs SYKDXCM vs WSTAll medical device stocks →All comparisons →
Track DXCM and MDLN
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.